Statement of Purpose
AIDS Treatment News is one of the primary treatment resources for community-based organizations and government agencies. Because of the insightful articles presented in each newsletter, case workers and counselors are consistently able to recommend AIDS Treatment News to their clients.
Physicians, counselors, and clinicians are among the many professionals who regularly turn to AIDS Treatment News for accurate, timely reporting. The New York Times, The Wall Street Journal, Cable News Network, Journal of the American Medical Association, and ABC and CBS News have all depended on AIDS Treatment News for vital information about the many facets of the AIDS epidemic.
AIDS Treatment News keeps you informed of public-policy developments, whether they involve changes in clinical trials or the drug-approval process. The newsletter can help you learn how to overcome obstacles in obtaining medication, and provides news about the prevention of illnesses commonly associated with HIV. AIDS Treatment News is your opportunity to have the latest information on AIDS treatments and public policy delivered directly to you, twice each month. Each issue will give you insight into treatments and options currently in use by physicians, and other medical professionals and people with AIDS/HIV. AIDS Treatment News is dedicated to giving you a thoroughly accurate publication with a style of writing that is useful for physicians, but accessible to people living with AIDS/HIV.
AIDS Treatment News
Published twice monthly, 24 times per year, on the first and third Friday of every month. Print copies are sent by first class mail. E-mail is available. Back issues are available.
Subscription and Editorial Office:
AIDS Treatment News
1233 Locust St., 5th floor
Philadelphia, PA 19107
800/804-8845 toll-free U.S. and Canada
215/546-3776 regular office number
e-mail: email@example.com or firstname.lastname@example.org
useful links: www.aidsnews.org
Editor and Publisher:
John S. James
Jennifer Cohn, Tadd T. Tobias, R.N.
Businesses, Institutions, Professionals: $325/year.
Nonprofit organizations: $150/year.
Individuals: $140/year, or $80 for six months. If you cannot afford a subscription, please write or call about our sliding scale.
Business, nonprofit, and full-rate individual subscribers can receive an early copy by e-mail, before the issue is printed, in addition to their regular copy at no extra charge. It's okay to direct the e-mail copy to someone else. Call our office to add e-mail to your subscription.
Outside North, Central, or South America, add air mail postage:
$20/year, $10 for six months.
Back issues available.
Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details.
Please send U.S. funds: Personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, American Express, and purchase orders also accepted.
Free e-mail: Free delivery for individuals (delayed one week). To subscribe, send a blank e-mail to: email@example.com.
Notice: AIDS Treatment News gladly provides its information without charge on the Internet. Since we began in January 1987, we have been supported only by subscriptions. We ask those in a position to do so to consider helping us meet expenses by subscribing to the printed edition of the newsletter, available world wide by first class mail/airmail.
Alternatively, you can help by making a tax-deductible contribution to AIDS Treatment News Associates. For more information, see AIDS Treatment News Associates (ATNA) Receives Nonprofit Status in AIDS Treatment News Issue #254, September 6, 1996. Or call Kevin Farrell, 415/241-0413, or Denny Smith, 415/750-4852.
ISSN # 1052-4207
Copyright 2003 by John S. James. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used.
Categories Covered:HIV/AIDS Outside the U.S., HIV Case Management and Social Work, Viramune (Nevirapine), HIV Drugs In Development, HIV Treatment and Medical Care, HIV Basic Science and Pathogenesis, Regional/Global Anti-HIV Efforts, Adverse Events, Comorbidities, and HIV, HIV Testing, Understanding HIV-Related Lab Tests, Vaccines and Microbicides for HIV, HIV Prevention and Transmission, Legal Issues, Norvir (Ritonavir), Financial Issues, Living Well With HIV, HIV-Related Policy Issues, HIV in Books and Publishing, History of HIV/AIDS, Viread (Tenofovir Disoproxil Fumarate), HIV Epidemiology, HIV and Mental Health Care, Tipranavir (Aptivus), PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention Methods, HIV Policy and Advocacy, HIV Treatment Strategies, Providing Quality HIV Care, HIV/AIDS Basics, People Under 30, Nevirapine (Viramune), Atazanavir (Reyataz), HIV Care and Services Outside the US, FDA-Approved HIV Medications, Switching or Stopping HIV Treatment, Physical Health Issues, Neuorlogical (Brain/Nerve) Issues and HIV, Reyataz (Atazanavir), Finding HIV Support Groups and Services, HIV Treatments in Development, Etravirine (Intelence), Nutrition and Fitness, HIV in Specific Countries, Ritonavir (Norvir), Mental Health, Stavudine (d4T, Zerit), Videx (Didanosine, ddI), Zidovudine (AZT, Retrovir), Emtriva (Emtricitabine, FTC), Ziagen (Abacavir), HIV Advocacy and Activism, Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Abacavir/Lamivudine (Epzicom, Kivexa), Flu (Influenza), Colds, and HIV, HIV Prevention for People With HIV, Managing HIV Drug Resistance, Abacavir/Lamivudine/Zidovudine (Trizivir), Abacavir (Ziagen), First-Line HIV Treatment, Body Fat, Lipodystrophy and HIV, Tools and Tips for HIV Advocacy, Myths About HIV/AIDS, Managing HIV Drug Resistance, Kaletra (Lopinavir/Ritonavir), Meeting the Costs of HIV Care, Enfuvirtide (T-20, Fuzeon), Switching or Stopping HIV Treatment, PEP (HIV Post-Exposure Prophylaxis), Spirituality and Religion, Tuberculosis and HIV, HIV Advocates in the Spotlight, Sustiva (Efavirenz, Stocrin), PrEP (HIV Pre-Exposure Prophylaxis)
Summary: Here are places to look if you need to find out about HIV travel restrictions and testing requirements of countries around the world. For example, a database of all countries is now being maintained in Europe, and made available through the ...
The number of people receiving antiretroviral treatment in developing countries increased 75% in one year, according to a January 26 report from the United Nations. The report was announced at the World Economic Forum in Davos, Switzerland, at a join...
Diver Greg Louganis and actor Chad Allen spoke about their struggles with depression at a public forum in New York (at the LGBT center on October 11), and will speak again in San Francisco on October 27, to raise awareness of the problem in the gay c...
More than 200 AIDS and other organizations and 2,700 individuals have endorsed the AIDSVote platform, put together by a nonpartisan group that informs candidates about AIDS issues and encourages individuals to vote. AIDSVote does not endorse candidat...
A recent report on two specialized scientific conferences looks at some of the most important current ideas on developing new kinds of HIV treatments. The conferences took place in April 2004, and the report,1 by immunologist Gareth Hardy, Ph.D., was...
On August 11, 2004, the Cambodian government ordered researchers not to proceed with a trial to test whether once-daily use of tenofovir (brand name Viread), a drug already widely used to treat HIV, could prevent new infections in healthy people. The...
The June 23 talk by President Bush in Philadelphia (see "President Bush on AIDS: More Questions Than Answers" in this issue) raised deeper issues that need attention.
There is common ground on abstinence; the problem is with abstinence-only (a phras...
A Congressionally mandated study sponsored by the U.S. Department of Health and Human Services has urged that the U.S. replace the current patchwork of Medicaid and other funding mechanisms with an HIV Comprehensive Care Program having "a strong focu...
June 9, 2004: The new Medicare-approved discount cards went into effect on June 1. They are the first step of a badly flawed but sometimes beneficial Medicare prescription-drug program, in which the U.S. government will spend hundreds of billions of ...